Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

Bob T. Li, Egbert F. Smit, Yasushi Goto et al. · New England Journal of Medicine · 2021 · 980 citations · Full text

Medicine, Oncology, Pharmacology +16

Intragenic ERBB2 kinase mutations in tumours

Philip Stephens, Chris Hunter, Graham R. Bignell et al. · Nature · 2004 · 791 citations

Medicine, Molecular Genetics, Oncology +12

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

Julien Mazières, Solange Peters, Benoît Lepage et al. · Journal of Clinical Oncology · 2013 · 659 citations

Medicine, Molecular Genetics, Oncology +15

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of <i>ERBB2</i> ( <i>HER2</i> ) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Maria E. Arcila, Jamie E. Chaft, Khédoudja Nafa et al. · Clinical Cancer Research · 2012 · 498 citations · Full text

Medicine, Oncology, Pathology +17